Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries

Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries

Source: 
Xconomy
snippet: 

Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis (NASH) and implementing a corporate restructuring that will cut 40 percent of its staff, splitting the remaining workforce into two distinct business units.